You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海王生物(000078.SZ)8天7漲停 下屬子公司有生產利巴韋林注射液
格隆匯 02-06 16:48

格隆匯2月6日丨海王生物(000078.SZ)公佈,公司股票價格於2020年2月4日、2月5日、2月6日連續三個交易日收盤價格漲幅偏離值累計超過20%,根據《深圳證券交易所交易規則》的相關規定,屬於股票交易異常波動的情況。

公司未發現近期有公共媒體報道了可能或已經對公司股票交易價格產生較大影響的未公開重大信息。針對“新型冠狀病毒感染的肺炎疫情”,公司已緊急成立疫情應急指揮小組,要求全國各分子公司上下聯動,全力保障藥品、器械、醫用耗材等防控物資的供應,盡一切可能優先保障醫院需求,為奮戰在疫情最前線的醫務工作者們提供強有力的後盾。

根據國家衞生健康委員會於202025日在其網站披露的《關於印發新型冠狀病毒感染的肺炎診療方案(試行第五版)的通知》,將藥品利巴韋林作為治療推薦用藥公司下屬子公司福州海王福藥製藥有限公司有生產利巴韋林注射液2018年度2019年度福州海王福藥製藥有限公司該藥品的銷售分別120元和103萬元公司將積極響應防疫需求組織生產

暫無法預計該事項對公司可能帶來的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account